Genetic Variants May Explain Why GLP-1 Drugs Like Ozempic Don't Work for Some Patients
Scientists have identified genetic variants that may cause some people to be less responsive to GLP-1 medications such as Ozempic. Approximately 10% of the population carries these variants, which appear to produce a form of 'GLP-1 resistance.' The finding could help explain treatment failures and eventually guide more personalized diabetes and obesity care.
Researchers have discovered specific genetic variants that may render GLP-1 receptor agonist drugs, including widely used medications like semaglutide (Ozempic, Wegovy), significantly less effective in a subset of patients. The variants, found in roughly 10% of the population, appear to interfere with the body's normal response to these drugs, a phenomenon scientists are calling 'GLP-1 resistance.' Evidence from multiple clinical trials showed that carriers of these variants were substantially less likely to achieve healthy blood sugar targets while on GLP-1 medications. The discovery offers a potential biological explanation for why some Type 2 diabetes patients fail to respond adequately to a drug class that has otherwise shown strong efficacy. If validated further, the findings could pave the way for genetic screening to identify non-responders before treatment begins, allowing clinicians to pursue alternative therapies earlier. This research adds to a growing body of work exploring how individual genetic makeup influences drug response, a cornerstone of precision medicine.
What's missing
The article does not specify which genes or variants are involved, the size or design of the clinical trials cited, or whether the research has been peer-reviewed and published in a journal, all of which are important for assessing the strength of the findings.
How coverage differed
Only one source was available for this story, Science Daily, which is rated center. The framing was straightforward and science-focused, without notable political or commercial slant, though the headline's use of the brand name 'Ozempic' rather than the generic drug class may reflect the drug's cultural prominence.
What different sources said
- Science DailyCenter
Scientists discover why ozempic may not work for some people
Related
U.S. Establishes Ebola Quarantine Center in Kenya Amid Local Protests and Legal Challenges
The United States is constructing a quarantine facility in Nanyuki, Kenya to isolate American citizens exposed to Ebola in Central Africa, sparking protests and a high court lawsuit from Kenyan residents who fear the virus could be introduced to their country. The facility reflects U.S. policy to prevent Ebola cases from entering the United States, though the Kenyan government has approved it as part of a bilateral partnership. Public health experts and local communities debate whether the facility enhances or undermines regional security and public health cooperation.
Study: Four Minutes of Daily Resistance Training Significantly Improves Fitness in Older Adults
A Penn State College of Medicine study published in PLOS One found that just 4 minutes of daily resistance training significantly improved strength in adults 65 and older within 12 weeks. The research suggests that even minimal daily exercise can substantially impact key health factors affecting fall risk, longevity, and independent living. The findings are notable because they demonstrate that meaningful fitness improvements for older adults may require less time commitment than commonly assumed.
Americans with Severe Obesity Receive Fewer Surgical Procedures Despite Rising Need
Researchers from LSU's Pennington Biomedical Research Center found that Americans with the highest levels of obesity are undergoing fewer surgical procedures overall, including common operations like joint replacements and cancer-related surgeries. The study examined trends across multiple surgical categories including hernia, breast, prostate, and colon procedures. This disparity is significant because it suggests potential barriers to necessary medical care for the most severely obese population.